137 related articles for article (PubMed ID: 33533659)
1. Harnessing the power of foot-and-mouth-disease virus for targeting integrin alpha-v beta-6 for the therapy of cancer.
Meecham A; Marshall J
Expert Opin Drug Discov; 2021 Jul; 16(7):737-744. PubMed ID: 33533659
[No Abstract] [Full Text] [Related]
2. Optimized serum stability and specificity of an αvβ6 integrin-binding peptide for tumor targeting.
Cardle II; Jensen MC; Pun SH; Sellers DL
J Biol Chem; 2021; 296():100657. PubMed ID: 33857478
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological Characterization of the αvβ6 Integrin Binding and Internalization Kinetics of the Foot-and-Mouth Disease Virus Derived Peptide A20FMDV2.
Slack RJ; Hafeji M; Rogers R; Ludbrook SB; Marshall JF; Flint DJ; Pyne S; Denyer JC
Pharmacology; 2016; 97(3-4):114-25. PubMed ID: 26734728
[TBL] [Abstract][Full Text] [Related]
4. Use of a peptide derived from foot-and-mouth disease virus for the noninvasive imaging of human cancer: generation and evaluation of 4-[18F]fluorobenzoyl A20FMDV2 for in vivo imaging of integrin alphavbeta6 expression with positron emission tomography.
Hausner SH; DiCara D; Marik J; Marshall JF; Sutcliffe JL
Cancer Res; 2007 Aug; 67(16):7833-40. PubMed ID: 17699789
[TBL] [Abstract][Full Text] [Related]
5. A Microdose PET Study of the Safety, Immunogenicity, Biodistribution, and Radiation Dosimetry of
Keat N; Kenny J; Chen K; Onega M; Garman N; Slack RJ; Parker CA; Lumbers RT; Hallett W; Saleem A; Passchier J; Lukey PT
J Nucl Med Technol; 2018 Jun; 46(2):136-143. PubMed ID: 29438002
[TBL] [Abstract][Full Text] [Related]
6. Preclinical evaluation of [
Onega M; Parker CA; Coello C; Rizzo G; Keat N; Ramada-Magalhaes J; Moz S; Tang SP; Plisson C; Wells L; Ashworth S; Slack RJ; Vitulli G; Wilson FJ; Gunn R; Lukey PT; Passchier J
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):958-966. PubMed ID: 31897589
[TBL] [Abstract][Full Text] [Related]
7. Clinical quantification of the integrin αvβ6 by [
Lukey PT; Coello C; Gunn R; Parker C; Wilson FJ; Saleem A; Garman N; Costa M; Kendrick S; Onega M; Kang'ombe AR; Listanco A; Davies J; Ramada-Magalhaes J; Moz S; Fahy WA; Maher TM; Jenkins G; Passchier J; Marshall RP
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):967-979. PubMed ID: 31814068
[TBL] [Abstract][Full Text] [Related]
8. Development and characterization of a
Ui T; Ueda M; Higaki Y; Kamino S; Sano K; Kimura H; Saji H; Enomoto S
Bioorg Med Chem; 2020 Jan; 28(1):115189. PubMed ID: 31740201
[TBL] [Abstract][Full Text] [Related]
9. High-resolution in vivo imaging of breast cancer by targeting the pro-invasive integrin alphavbeta6.
Saha A; Ellison D; Thomas GJ; Vallath S; Mather SJ; Hart IR; Marshall JF
J Pathol; 2010 Sep; 222(1):52-63. PubMed ID: 20629113
[TBL] [Abstract][Full Text] [Related]
10. The Effect of Bi-Terminal PEGylation of an Integrin αvβ₆-Targeted ¹⁸F Peptide on Pharmacokinetics and Tumor Uptake.
Hausner SH; Bauer N; Hu LY; Knight LM; Sutcliffe JL
J Nucl Med; 2015 May; 56(5):784-90. PubMed ID: 25814519
[TBL] [Abstract][Full Text] [Related]
11. Targeted in vivo imaging of integrin alphavbeta6 with an improved radiotracer and its relevance in a pancreatic tumor model.
Hausner SH; Abbey CK; Bold RJ; Gagnon MK; Marik J; Marshall JF; Stanecki CE; Sutcliffe JL
Cancer Res; 2009 Jul; 69(14):5843-50. PubMed ID: 19549907
[TBL] [Abstract][Full Text] [Related]
12. Preclinical SPECT/CT imaging of αvβ6 integrins for molecular stratification of idiopathic pulmonary fibrosis.
John AE; Luckett JC; Tatler AL; Awais RO; Desai A; Habgood A; Ludbrook S; Blanchard AD; Perkins AC; Jenkins RG; Marshall JF
J Nucl Med; 2013 Dec; 54(12):2146-52. PubMed ID: 24167080
[TBL] [Abstract][Full Text] [Related]
13. The Novel Oncolytic Adenoviral Mutant Ad5-3Δ-A20T Retargeted to αvβ6 Integrins Efficiently Eliminates Pancreatic Cancer Cells.
Man YKS; Davies JA; Coughlan L; Pantelidou C; Blázquez-Moreno A; Marshall JF; Parker AL; Halldén G
Mol Cancer Ther; 2018 Feb; 17(2):575-587. PubMed ID: 29367266
[TBL] [Abstract][Full Text] [Related]
14. In vivo retargeting of adenovirus type 5 to alphavbeta6 integrin results in reduced hepatotoxicity and improved tumor uptake following systemic delivery.
Coughlan L; Vallath S; Saha A; Flak M; McNeish IA; Vassaux G; Marshall JF; Hart IR; Thomas GJ
J Virol; 2009 Jul; 83(13):6416-28. PubMed ID: 19369326
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of [64Cu]Cu-DOTA and [64Cu]Cu-CB-TE2A chelates for targeted positron emission tomography with an alphavbeta6-specific peptide.
Hausner SH; Kukis DL; Gagnon MK; Stanecki CE; Ferdani R; Marshall JF; Anderson CJ; Sutcliffe JL
Mol Imaging; 2009; 8(2):111-21. PubMed ID: 19397856
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and Systematic Study on the Effect of Different PEG Units on Stability of PEGylated, Integrin-αvβ6-Specific A20FMDV2 Analogues in Rat Serum and Human Plasma.
Hung KY; Kowalczyk R; Desai A; Brimble MA; Marshall JF; Harris PWR
Molecules; 2022 Jul; 27(14):. PubMed ID: 35889207
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Two Optical Probes for Imaging the Integrin α
Ganguly T; Tang SY; Bauer N; Sutcliffe JL
Mol Imaging Biol; 2020 Oct; 22(5):1170-1181. PubMed ID: 32002763
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
